Minerva Neurosciences, Inc (NERV) Shares Bought by Vanguard Group Inc.
Vanguard Group Inc. lifted its stake in shares of Minerva Neurosciences, Inc (NASDAQ:NERV) by 14.4% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,074,239 shares of the biopharmaceutical company’s stock after buying an additional 134,942 shares during the period. Vanguard Group Inc. owned about 2.93% of Minerva Neurosciences worth $9,507,000 as of its most recent SEC filing.
Other large investors also recently made changes to their positions in the company. Rhumbline Advisers increased its holdings in shares of Minerva Neurosciences by 35.9% during the second quarter. Rhumbline Advisers now owns 27,082 shares of the biopharmaceutical company’s stock worth $240,000 after buying an additional 7,150 shares in the last quarter. State of Wisconsin Investment Board acquired a new position in shares of Minerva Neurosciences during the second quarter worth $159,000. Laurion Capital Management LP acquired a new position in shares of Minerva Neurosciences during the second quarter worth $326,000. Bank of New York Mellon Corp increased its holdings in shares of Minerva Neurosciences by 13.4% during the second quarter. Bank of New York Mellon Corp now owns 90,929 shares of the biopharmaceutical company’s stock worth $805,000 after buying an additional 10,728 shares in the last quarter. Finally, Alps Advisors Inc. increased its holdings in shares of Minerva Neurosciences by 10.6% during the second quarter. Alps Advisors Inc. now owns 33,131 shares of the biopharmaceutical company’s stock worth $293,000 after buying an additional 3,187 shares in the last quarter. Institutional investors own 79.53% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Minerva Neurosciences, Inc (NERV) Shares Bought by Vanguard Group Inc.” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright laws. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/11/24/minerva-neurosciences-inc-nerv-shares-bought-by-vanguard-group-inc.html.
Minerva Neurosciences, Inc (NERV) opened at $5.40 on Friday. Minerva Neurosciences, Inc has a 1-year low of $4.80 and a 1-year high of $14.15.
Minerva Neurosciences (NASDAQ:NERV) last announced its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter. During the same period in the prior year, the business posted ($0.24) EPS. analysts anticipate that Minerva Neurosciences, Inc will post -1.28 earnings per share for the current year.
Minerva Neurosciences Profile
Minerva Neurosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson’s disease.
Want to see what other hedge funds are holding NERV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Minerva Neurosciences, Inc (NASDAQ:NERV).
Receive News & Stock Ratings for Minerva Neurosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences Inc and related stocks with our FREE daily email newsletter.